Press Releases
November 30, 2022
BOSTON --(BUSINESS WIRE)--Nov. 30, 2022-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of
November 30, 2022
BOSTON --(BUSINESS WIRE)--Nov. 30, 2022-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of
November 10, 2022
BOSTON --(BUSINESS WIRE)--Nov. 10, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that it has initiated startup activities for the global
November 3, 2022
BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the
October 3, 2022
Aura to Host Virtual Investor Day at 11:30 a.m. Eastern Time BOSTON --(BUSINESS WIRE)--Oct. 3, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced
September 27, 2022
Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022 , at 11:30 a.m. Eastern Time BOSTON --(BUSINESS WIRE)--Sep. 27, 2022-- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate
Displaying 1 - 10 of 27